AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04959175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: begins on day +5 at a dose of 5 mcg/kg/day (actual body weight) IV or subcutaneously, until the absolute neutrophil count is > 1,000/mm3 over the course of three days or > 5,000/mm3 on one day. Rounding to the nearest vial is allowed. G-CSF may be stopped early or not administered if required by the clinical circumstance. Additional G-CSF may be administered as warranted.
Study NCT04959175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Pre-transplant: 14.5 mg/kg/day IV daily for 2 days pre-transplant (Pre-Transplant days -6 and -5). Post-transplant: 25 mg/kg/day or 35 mg/kg/day (Post-transplant days +3 and +4).
Study NCT04959175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 25 or 35 mg/kg (equal to the cyclophosphamide dose) as IV infusion concomitant with cyclophosphamide. Mesna may or may not be given with the pre-transplant cyclophosphamide depending on institutional practice.
Study NCT04959175 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: 400 centigray (cGy) to be delivered in 2 fractions as 200 cGy per fraction twice daily. Pre-Transplant Day -1 (or Day 0 prior to graft administration)
Study NCT06234969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Theta Burst Stimulation to the Intraparietal Sulcus
Description: Continuous Theta Burst Stimulation delivered to the Intraparietal Sulcus
Study NCT06234969 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Continuous Theta Burst Stimulation
Description: Sham Continuous Theta Burst Stimulation
Study NCT05951491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Shoulder Exoskeleton
Description: The wearable shoulder exoskeleton prototype is under development at the University of Idaho to provide gravity support to the shoulder. Subjects will use the device at home for a period of 5-7 days for at least 2 hours per day.
Study NCT05951491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Hand Exoskeleton
Description: The wearable hand exoskeleton prototype is under development at the University of Idaho to provide hand-opening support. Subjects will use the device at home for a period of 5-7 days for at least 2 hours per day.
Study NCT05970107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Lymph Node Dissection
Description: ALND happens after cancer cells are found during a sentinel lymph node biopsy.~ALND can remove lymph nodes located above, below or directly underneath a muscle that runs along the side of the upper chest.
Study NCT05970107 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary Lymph Node Dissection
Description: ALND happens after cancer cells are found during a sentinel lymph node biopsy.~ALND can remove lymph nodes located above, below or directly underneath a muscle that runs along the side of the upper chest.
Study NCT05970107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Reverse Mapping
Description: Axillary reverse mapping (ARM) is a technique where blue dye is injected into the upper arm at surgery, allowing direct visualization of arm lymphatics and nodes during ALND
Study NCT05970107 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary Reverse Mapping
Description: Axillary reverse mapping (ARM) is a technique where blue dye is injected into the upper arm at surgery, allowing direct visualization of arm lymphatics and nodes during ALND
Study NCT05970107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphaticovenous Bypass
Description: Lymphaticovenous bypass/anastomosis (LVB/LVA) involves supramicrosurgery in which the blocked lymphatic vessel of an affected limb is connected to a nearby vein with the aid of ultra-fine instruments and a powerful operating microscope.
Study NCT06445517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISM8207
Description: Pharmaceutical formulation: Capsules Mode of Administration: Oral
Study NCT04912024 — intervention group
Intervention type: DEVICE
Intervention: Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System
Description: Intermittent renal replacement therapy using the Tablo Hemodialysis System in the acute setting for participants with AKI or ESKD
Study NCT04912024 — intervention group
Intervention type: DEVICE
Intervention: Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems
Description: Intermittent renal replacement therapy using Conventional Hemodialysis Systems in the acute setting for participants with AKI or ESKD
Study NCT04921358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: administered intravenously
Study NCT04921358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: administered intravenously
Study NCT04921358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: administered orally
Study NCT05107362 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: untrained lay user performs investigational diagnostic test
Description: Untrained lay users (parents/guardians of pediatric subjects or friends/family members of adult subjects) collect throat swab specimens and perform the investigational diagnostic test.
Study NCT04190056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04190056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Given PO
Study NCT04190056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT05343247 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cameriere method
Description: Cameriere et al. designed a quantitative approach through a formula based on sex and the ratio between length and apex opening measurements of each lower left tooth.
Study NCT05343247 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: London Atlas method
Description: The London Atlas requires the user to assess the tooth development and eruption and then match it to one of the 31 pictures of age categories.
Study NCT03946761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer goggle system
Description: -The cancer goggle system is being used as a non-significant risk device
Study NCT05921370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg
Description: This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.~silodosin is an alpha blocker which act to dilate the ureter to facilitate access sheath placement
Study NCT05921370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.~Group B (the control group): Patients will receive Placebo for 7 days before their scheduled retrograde intrarenal surgery.
Study NCT04686097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: treatment: puncture of coagulation
Description: ultrasound-guided puncture of coagulation
Study NCT04686097 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: treatment: sclerosing agent injected
Description: ultrasound-guided sclerosing agent injected
Study NCT06461520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maze Balance board
Description: Every child will have their balance evaluated using the SWOC tool, CTSIB, and Pediatric Balance Scale. Patients performed a range of proprioceptive exercises, such as static one-leg standing, board balancing, squatting, and 20 minutes of straight-line walking on a hard surface before moving to a foam surface. For 20 minutes each session, proprioceptive exercises were conducted with open eyes first, followed by closed ones. The training program for the maze balancing board will next take place. There will be seven phases to the maze balance board training; each stage will last for two days and there will be three sessions per day, each lasting an hour.
Study NCT06461520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive training
Description: This group will get proprioceptive training. For a total of ten weeks, the intervention will be carried out three times a week for forty minutes each. Without maze-balance board training, the training schedule will consist of three sessions each week, lasting ten minutes each for preparatory, twenty minutes for proprioceptive, and ten minutes for restorative activities. Every meeting ended with a 10-minute cool-down and 10-minute warm-up to signify the quality of work.
Study NCT06461520 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proprioceptive training
Description: This group will get proprioceptive training. For a total of ten weeks, the intervention will be carried out three times a week for forty minutes each. Without maze-balance board training, the training schedule will consist of three sessions each week, lasting ten minutes each for preparatory, twenty minutes for proprioceptive, and ten minutes for restorative activities. Every meeting ended with a 10-minute cool-down and 10-minute warm-up to signify the quality of work.
Study NCT06189092 — intervention group
Intervention type: DRUG
Intervention: Bleomycin
Description: Using electroporation to infuse bleomycin in the lesion
Study NCT06566274 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thumbtack needle
Description: As a kind of intradermal needle, thumbtack needle (TTN) is a method of shallow puncture and long-term needle.After the TTN is attached into the acupoints, it will be reserved in the acupoints for 3 days. After 3 days of retention of TTN, the patient is instructed to go to the hospital, where the doctor removes the needle, disinfect the local skin of acupoints and conducts the next TTN treatment. A total of 5 treatments were applied for a duration of 15 days.
Study NCT05563142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deploying vascular closure device versus manual compression
Description: patients will be randomized to either group 1 or group 2 in a 1:1 ratio:
Study NCT05563142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: deploying vascular closure device versus manual compression
Description: patients will be randomized to either group 1 or group 2 in a 1:1 ratio:
Study NCT06566274 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham thumbtack needle
Description: The sham TTN used in the sham TTN group has no needle body and its appearance and shape are similar to the real TTN. But it does not produce a needle-like effect.~The acupoints of sham TN group are the same as those of TN group. The use of sham TN is the same as that of the TN group. After 3 days retention of sham TN, the patient will be instructed to go to the hospital, where the doctor remove the sham TN, and conduct the next treatment after local skin disinfection. A total of 5 treatments will be applied for a duration of 15 days.
Study NCT05197049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 1
Description: Guselkumab (Dose 1) will be administered by subcutaneous (SC) injection.
Study NCT05197049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 2
Description: Guselkumab (Dose 2) will be administered by SC injection.
Study NCT05197049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 3
Description: Guselkumab (Dose 3) will be administered by SC injection.
Study NCT05197049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by SC injection.
Study NCT05421078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obicetrapib
Description: tablet
Study NCT05421078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active ingredient
Study NCT06451523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alliance180 Program
Description: The Alliance180 Program promotes feelings of neuropsychological safety and trust in the context of a 3-day program, which includes the transformative equine experience.
Study NCT04368702 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Viewray MRIdian® Linac
Description: MR-image guided radiation will be administered per disease site standards.
Study NCT05074433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casirivimab+imdevimab
Description: Co-administered sequentially subcutaneous (SC)
Study NCT05074433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT04909879 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-MSC
Description: COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
Study NCT04909879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Excipient solution
Study NCT06537336 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QoL
Description: QoL measurements were conducted using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-Core30 (EORTC-QLQ-C30).
Study NCT06537336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QoL
Description: QoL measurements were conducted using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-Core30 (EORTC-QLQ-C30).
Study NCT06537336 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lung function
Description: lung function tests using spirometry
Study NCT06537336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lung function
Description: lung function tests using spirometry
Study NCT06264765 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: scalp block
Description: The scalp block will be performed by the anesthesiologist 10 minutes before the pin head holder application (PHHA). Supraorbital and supratrochlear nerves will be blocked bilaterally with 6 ml of 0.5% bupivacaine injected vertically into the skin above the eyebrow midline. Auriculotemporal nerves will be blocked bilaterally by injecting 4 ml of 0.5% bupivacaine 1.5 cm anterior to the ear at the tragus level. The needle will be inserted perpendicular to the skin and the fascia will be injected deeply and superficially while the needle is withdrawn. Postauricular branches of the greater auricular nerves will be blocked bilaterally with 2 ml of 0.5% bupivacaine injected 1 cm posterior to the ear, between the bone and skin, at the level of the tragus. The greater, lesser, and third occipital nerves run along the upper nuchal line approximately halfway between the occipital prominence and the mastoid prominence.
Study NCT06264765 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Incisional infiltration
Description: Incisional infiltration: 20 ml of 0.5% bupivacaine will be infiltrated by the surgeon into the PHHA points and surgical incision areas 10 minutes before PHHA. Two
Study NCT06271226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: With acupressure, massage or pressure is applied to certain points on the body with fingers, hands or palms. The pressed points are the points on the skin that are sensitive to bioelectrical impulses and can easily transmit them.
Study NCT06271226 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo acupressure
Description: n the placebo group, the preparations and forms applied to the experimental group will be applied in the same way, but in accordance with the literature, an area 1.5 cm away from the acupressure point that has no connection with the acupressure point will be selected and the application will be made in the form of light touch
Study NCT06271226 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: During the study, pain and physiological parameters will be monitored and recorded twice a day (morning and evening) for 2 days, without any application (other than the routine treatment given by the physician).
Study NCT06246630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy and targeted-therapy guided by organoid drug sensitivity test
Description: this study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment, and the study aims to evaluate the clinical effectiveness of the drug and its consistency with in vitro organoid drug sensitivity.
Study NCT05434975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block
Description: For single shot-ISBP block, 15 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine, a total of 25 ml of local anesthetic, will be administered to all patients.~For the block procedure, an imaginary horizontal line drawn from the thyroid cartilage to the sternocleidomastoid (SCM) muscle will followed and the lateral of the SCM muscle will be cleaned with povidine iodine. At the C6 level to be blocked, the nerve roots will be detected by ultrasound. 25 ml of local anesthetic will be injected around the plexus roots with a 22 G 80 mm echogenic needle. The distribution of the local anesthetic applied to the area, which expands the tissues and separates the nerve roots from other tissues, will be seen on ultrasound.
Study NCT05150340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-771
Description: Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
Study NCT05511155 — intervention group
Intervention type: OTHER
Intervention: Oxygen therapy
Description: Oxygen therapy will be given for 15 minutes with a non-rebreathing mask.
Study NCT05375487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbonated Natural Mineral Water
Description: 750 mL/day of carbonated natural mineral water, with high content of bicarbonate, calcium, and magnesium, in three portions of 250 mL (one portion 30 minutes prior to lunch, one during the afternoon and the last portion minutes before dinner), during 4 weeks.
Study NCT05375487 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low Mineral Water
Description: 750 mL/day of low mineral water (one third prior to lunch, one third during the afternoon and the last third 30 minutes before dinner), during 4 weeks.
Study NCT03676439 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Spinal Stimulation
Description: Spinal Magnetic Stimulation (TMS) on Lateral Cord Stimulation (LCS), in the search of the improvement of the tone, motor function and speech, in patients with spastic cerebral Palsy.~Due to its non-invasiveness and possible efficacy, the use of Magnetic Spinal Stimulation is proposed to try to prove its therapeutic usefulness.~This is the phase 2/3 clinical test of the method, in the future, and as its use could be extended, if the results were positive, its indications could be extended to other pathological conditions, giving a greater spectrum of spastic patients, potentially benefited.
Study NCT03676439 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Spinal Stimulation
Description: Spinal Magnetic Stimulation (TMS) on Lateral Cord Stimulation (LCS), in the search of the improvement of the tone, motor function and speech, in patients with spastic cerebral Palsy.~Due to its non-invasiveness and possible efficacy, the use of Magnetic Spinal Stimulation is proposed to try to prove its therapeutic usefulness.~This is the phase 2/3 clinical test of the method, in the future, and as its use could be extended, if the results were positive, its indications could be extended to other pathological conditions, giving a greater spectrum of spastic patients, potentially benefited.
Study NCT04863976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Description: Dynamic movements of the joints controlled by the quadriceps muscle (hip and knee)
Study NCT04863976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive stretching
Description: passive stretching of the quadriceps muscle
Study NCT04863976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-stretching
Description: Self-stretching of the quadriceps muscle
Study NCT04698161 — intervention group
Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
Study NCT04698161 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
Study NCT04698161 — intervention group
Intervention type: OTHER
Intervention: Medical examination
Description: Blood pressure measurement, abdominal and thoracic physical examination
Study NCT06442501 — intervention group
Intervention type: OTHER
Intervention: routine care
Description: routine care
Study NCT04333680 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Focused Assessment of Sonography for Trauma Exam
Description: Speed and image quality of ultrasound exams performed with either transducer specified in the arms.